drugset

drugset / Trial / NCT00311012

SPP100 Dose Finding Study in Japan

NCT00311012 ↗

Phase 2 Completed 445 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.

Timeline

Start: 2004-08
Primary completion: 2005-03
Completion: 2005-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	—	—

Indications